A Phase 1 Dose Escalation Study of the Tolerability, Safety, Efficacy and Pharmacokinetics of ZG006 in Patients with Small Cell Lung Cancer
Latest Information Update: 25 Sep 2024
At a glance
- Drugs ZG-006 (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions
- Sponsors Suzhou Zelgen Biopharmaceuticals
- 25 Sep 2024 New trial record